Vyriad

company

About

Vyriad is a clinical stage biopharmaceutical company.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
$29.50M
Industries
Biotechnology
Founded date
Jan 1, 2016
Number Of Employee
11 - 50
Operating Status
Active

Vyriad is a clinical-stage company developing proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. The potentially life-changing oncolytic viral technologies of Vyriad are the result of decades of research by dedicated researchers and clinicians at Mayo Clinic and the University of Miami.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$29.50M
Vyriad has raised a total of $29.50M in funding over 2 rounds. Their latest funding was raised on May 17, 2022 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 17, 2022 Series B $29.50M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Vyriad is funded by 1 investors. Regeneron are the most recent investors.
Investor Name Lead Investor Funding Round
Regeneron Series B